Vor Biopharma IncNASDAQ:VOR
- LAST PRICE1.8300
- TODAY'S CHANGE (%)-0.0500 (-2.6596%)
- Bid / Lots1.8300/ 10
- Ask / Lots1.8500/ 4
- Open / Previous Close1.8600 / 1.8800
- Day Range
- 52 Week Range
- Volume12,500
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VOR |
|---|---|---|
| 09:32 ET | 1884 | 1.86 |
| 09:34 ET | 1974 | 1.87 |
| 09:39 ET | 100 | 1.85 |
| 09:41 ET | 100 | 1.85 |
| 09:45 ET | 490 | 1.85 |
| 09:52 ET | 200 | 1.85 |
| 09:54 ET | 100 | 1.85 |
| 09:57 ET | 387 | 1.85 |
| 10:01 ET | 100 | 1.83 |
| 10:08 ET | 100 | 1.82 |
| 10:10 ET | 3100 | 1.82 |
| 10:12 ET | 100 | 1.82 |
| 10:14 ET | 1819 | 1.82 |
| 10:15 ET | 100 | 1.82 |
| 10:17 ET | 100 | 1.83 |
| 10:19 ET | 100 | 1.83 |
Yesterday
Apr 1, 2024
Vor Bio to Participate in Upcoming Investor Conferences, from 8:00AM ET on Monday Apr 01, 2024 by Dow Jones
8:00AM ET on Monday Apr 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Vor Biopharma Inc | 128.2M | -1.0x | --- |
Annovis Bio Inc | 130.8M | -2.0x | --- |
Vistagen Therapeutics Inc | 130.5M | -1.4x | --- |
Leap Therapeutics Inc | 122.4M | -0.6x | --- |
Citius Pharmaceuticals Inc | 122.1M | -2.9x | --- |
GlycoMimetics Inc | 118.3M | -3.3x | --- |
Company Information
Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Company’s lead engineered hematopoietic stem cells (eHSC) product candidate include tremtelectogene empogeditemcel (trem-cel), for the treatment for acute myeloid leukemia (AML) and other blood cancers. It is designed to replace the standard of care in transplant settings for patients suffering from acute myeloid leukemia (AML) and other blood cancers. Its VBP101 is a Phase I/II a multicenter, open-label, first-in-human study of trem-cel in patients with AML.
Contact Information
- Headquarters
- 100 Cambridgepark Drive, Suite 101CAMBRIDGE, MA, United States 02140
- Phone
- 617-655-6580
- Fax
- 302-655-5049
Executives
- Non-Executive Independent Chairman of the Board
- Matthew Patterson
- President, Chief Executive Officer, Director
- Robert Ang
- Chief Financial Officer
- Nathan Jorgensen
- Chief Scientific Officer
- Tirtha Chakraborty
- Chief Medical Officer
- Eyal Attar
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $128.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 68.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.75 |
Book Value | $2.22 |
P/E Ratio | -1.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
